This trial is active, not recruiting.

Condition rhegmatogenous retinal detachment
Treatment colchicine
Phase phase 3
Sponsor Shahid Beheshti Medical University
Start date March 2004
End date August 2006
Trial identifier NCT00370201, 8259


This clinical trial will test the efficacy and safety of oral colchicine in prevention of proliferative vitreoretinopathy (PVR) in cases of rhegmatogenous retinal detachment

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double-blind
Primary purpose treatment

Primary Outcomes

proliferative vitreoretinopathy
time frame:
retinal reattachment rate
time frame:

Secondary Outcomes

visual acuity
time frame:
time frame:
macular pucker
time frame:

Eligibility Criteria

Male or female participants from 18 years up to 65 years old.

Inclusion Criteria: - Rhegmatogenous retinal detachment Exclusion Criteria: - PVR grade C - Duration of retinal detachment ≥ one month - History of cataract surgery - History of RD surgery

Additional Information

Principal investigator Hamid Ahmadieh, MD
Trial information was received from ClinicalTrials.gov and was last updated in October 2006.
Information provided to ClinicalTrials.gov by Shahid Beheshti Medical University.